Computational screening, synthesis and neuroprotective evaluation of small molecule for the treatment of alzheimer's disease
DOI:
https://doi.org/10.17533/udea.vitae.v31n3a354271Keywords:
Alzheimer’s disease, Beta secretase, cyclin-dependent kinase 5, drug-like, gamma secretase, neurodegenerative, pin1Abstract
BACKGROUND: Current treatments for Alzheimer’s disease primarily address symptoms, as no definitive therapeutic targets have been identified.
OBJECTIVES: This study aims to conduct a virtual screening of small molecules and synthesize and evaluate one of the most promising candidates for Alzheimer’s therapy.
METHODS: Using AutoDock Vina, compounds with drug-like properties were docked against key proteins implicated in Alzheimer's pathology: β-Secretase, γ-Secretase, Pin1, and Cdk5. The molecule with the highest in silico affinity (PubChem ID: 84378305) was synthesized and evaluated experimentally. Cytotoxicity and neuroprotective effects were assessed using the MTT assay in the presence of the Aβ25-35 peptide.
RESULTS: Four candidate molecules showed strong binding affinity, ranging from -6.8 to -9.1 kcal/mol. The results showed that when SK-N-SH cells were simultaneously treated with Aß25-35 peptide (5 µM) and compound 84378305 (0,1 µM), the molecule exhibited significant neuroprotection (33%) after the 48 h of incubation.
CONCLUSION: Findings indicate that this lead compound exhibits potential neuroprotective activity, highlighting its promise as a candidate for further development in Alzheimer’s disease treatment.
Downloads
References
Lukiw WJ. MicroRNA (miRNA) Complexity in Alzheimer’s Disease (AD). Biology. 2023;12(6):788. DOI: https://doi.org/10.3390/biology12060788
Xu J, Wang F, Guo J, Xu C, Cao Y, Fang Z, et al.Pharmacological Mechanisms Underlying the Neuroprotective Effects of Alpinia oxyphylla Miq. on Alzheimer’s Disease. Int J Mol Sci. 2020;21(6):2071. PMID: 32197305; PMCID: PMC7139528. DOI: https://doi.org/10.3390/ijms21062071
Guzior N, Ćkowska AW, Panek D, Malawska B. Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimer’s Disease. Curr Med Chem. 2015;22(3):373–404. DOI: https://doi.org/10.2174/0929867321666141106122628
Ambure P, Kar S, Roy K. Pharmacophore mapping-based virtual screening followed by molecular docking studies in search of potential acetylcholinesterase inhibitors as anti-Alzheimer's agents. Biosystems. 2014;116:10–20. DOI: https://doi.org/10.1016/j.biosystems.2013.12.002
Amanatkar HR, Papagiannopoulos B, Grossberg GT. Analysis of recent failures of disease modifying therapies in Alzheimer’s disease suggesting a new methodology for future studies. Expert Rev Neurother. 2017;17(1):7–16. DOI: https://doi.org/10.1080/14737175.2016.1194203
Liu J, Yin F, Guo L, Zhang J, Zidichouski J. Molecular mechanisms of geniposide and genipin against Alzheimer’s disease. In: Bioactive Nutraceuticals and Dietary Supplements in Neurological and Brain Disease. Elsevier; 2014. p. 221–27. DOI: https://doi.org/10.1016/B978-0-12-411462-3.00024-2
Sang Z, Qiang X, Li Y, Yuan W, Liu Q, Shi Y, et al.Design, synthesis and evaluation of scutellarein-O-alkylamines as multifunctional agents for the treatment of Alzheimer's disease. Eur J Med Chem. 2015;94:348–66. DOI: https://doi.org/10.1016/j.ejmech.2015.02.063
Pastorino L, Lu KP. Pathogenic mechanisms in Alzheimer's disease. Eur J Pharmacol. 2006;545(1):29–38. DOI: https://doi.org/10.1016/j.ejphar.2006.06.078
Reitz C, Mayeux R. Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol. 2014;88(4):640–51. DOI: https://doi.org/10.1016/j.bcp.2013.12.024
Thummayot S, Tocharus C, Pinkaew D, Viwatpinyo K, Sringarm K, Tocharus J. Neuroprotective effect of purple rice extract and its constituent against amyloid beta-induced neuronal cell death in SK-N-SH cells. NeuroToxicology. 2014;45:149–58. DOI: https://doi.org/10.1016/j.neuro.2014.10.010
Thummayot S, Tocharus C, Pinkaew D, Viwatpinyo K, Sringarm K, Tocharus J. Neuroprotective effect of purple rice extract and its constituent against amyloid beta-induced neuronal cell death in SK-N-SH cells. NeuroToxicology. 2014;45(Supplement C):149–58. DOI: https://doi.org/10.1016/j.neuro.2014.10.010
Abdalla A. Tau protein as a target for Alzheimer’s disease management. Saudi Pharm J. 2015;23(4):405–6. DOI: https://doi.org/10.1016/j.jsps.2015.01.017
Liu Y, Yang X, Lei Q, Li Z, Hu J, Wen X, et al.PEG–PEI/siROCK2 Protects Against Aβ42-Induced Neurotoxicity in Primary Neuron Cells for Alzheimer Disease. Cell Mol Neurobiol. 2015;35(6):841–48. DOI: https://doi.org/10.1007/s10571-015-0178-6
Lublin AL, Link CD. Alzheimer’s Disease Drug Discovery: In-vivo screening using C. elegans as a model for β-amyloid peptide-induced toxicity. Drug Discov Today Technol. 2013;10(1):e115–9. DOI: https://doi.org/10.1016/j.ddtec.2012.02.002
Scarpini E, Schelterns P, Feldman H. Treatment of Alzheimer's disease; current status and new perspectives. Lancet Neurol. 2003;2(9):539–47. DOI: https://doi.org/10.1016/S1474-4422(03)00502-7
Kumar A, Singh A, Ekavali. A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacol Rep. 2015;67(2):195–203. DOI: https://doi.org/10.1016/j.pharep.2014.09.004
Rampa A, Tarozzi A, Mancini F, Pruccoli L, Di Martino R, Gobbi S, et al.Naturally Inspired Molecules as Multifunctional Agents for Alzheimer’s Disease Treatment. Molecules. 2016;21(5):643. DOI: https://doi.org/10.3390/molecules21050643
Waqar M, Batool S. In silico analysis of binding of neurotoxic venom ligands with acetylcholinesterase for therapeutic use in treatment of Alzheimer’s disease. J Theor Biol. 2015;372:107–17. DOI: https://doi.org/10.1016/j.jtbi.2015.02.028
Sasidharan S, Gosu V, Tripathi T, Saudagar P. Molecular Dynamics Simulation to Study Protein Conformation and Ligand Interaction. In: Saudagar P, Tripathi T, editors. Protein Folding Dynamics and Stability. Springer; 2023. p. 6. DOI: https://doi.org/10.1007/978-981-99-2079-2_6
Roy S, Kumar A, Baig MH, Masařík M, Provazník I. Virtual screening, ADMET profiling, molecular docking and dynamics approaches to search for potent selective natural molecules based inhibitors against metallothionein-III to study Alzheimer’s disease. Methods. 2015;83:105–10. DOI: https://doi.org/10.1016/j.ymeth.2015.04.021
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem. 2010;31(2):455–71. DOI: https://doi.org/10.1002/jcc.21334
O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: An open chemical toolbox. J Cheminform. 2011;3(1):33. DOI: https://doi.org/10.1186/1758-2946-3-33
Leeson P. Drug discovery: Chemical beauty contest. Nature. 2012;481(7382):455–6. DOI: https://doi.org/10.1038/481455a
Veber DF, Johnson SR, Cheng H-Y, Smith BR, Ward KW, Kopple KD. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J Med Chem. 2002;45(12):2615–23. DOI: https://doi.org/10.1021/jm020017n
Ghose AK, Viswanadhan VN, Wendoloski JJ. A Knowledge-Based Approach in Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery. 1. A Qualitative and Quantitative Characterization of Known Drug Databases. J Comb Chem. 1999;1(1):55–68. DOI: https://doi.org/10.1021/cc9800071
Pájaro-Castro N, Flechas MC, Ocazionez R, Stashenko E, Olivero-Verbel JT. Potential interaction of components from essential oils with dengue virus proteins. BLaCPMA. 2015;14(3):141–55.
Holt PA, Chaires JB, Trent JO. Molecular Docking of Intercalators and Groove-Binders to Nucle
Jung HA, Ali MY, Choi RJ, Jeong HO, Chung HY, Choi JS. Kinetics and molecular docking studies of fucosterol and fucoxanthin, BACE1 inhibitors from brown algae Undaria pinnatifida and Ecklonia stolonifera. Food Chem Toxicol. 2016;89:104-111. DOI: http://dx.doi.org/10.1016/j.fct.2016.01.014
Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785-2791. DOI: https://doi.org/10.1002/jcc.21256
Ramachandran V, Padmanaban E, Ponnusamy K, Naidu S, Natesan M. Pharmacophore based virtual screening for identification of marine bioactive compounds as inhibitors against macrophage infectivity potentiator (Mip) protein of Chlamydia trachomatis. RSC Adv. 2016;6(23):18946-18957. DOI: https://doi.org/10.1039/c5ra24999f
Driver JA, Zhou XZ, Lu KP. Pin1 dysregulation helps to explain the inverse association between cancer and Alzheimer's disease. BBA-Gen Subjects. 2015;1850(10):2069-2076. DOI: https://doi.org/10.1016/j.bbagen.2014.12.025
Chen CH, Li W, Sultana R, You MH, Kondo A, Shahpasand K, et al.Pin1 cysteine-113 oxidation inhibits its catalytic activity and cellular function in Alzheimer’s disease. Neurobiol Dis. 2015;76:13-23. DOI: https://doi.org/10.1016/j.nbd.2014.12.027
De Strooper B. Aph-1, Pen-2, and Nicastrin with presenilin generate an active γ-secretase complex. Neuron. 2003;38(1):9-12. DOI: https://doi.org/10.1016/S0896-6273(03)00205-8
Wolfe MS. Inhibition and modulation of γ-secretase for Alzheimer’s disease. Neurotherapeutics. 2008;5(3):391-398. DOI: https://doi.org/10.1016/j.nurt.2008.05.010
Ekiri Vaidyanathan Raman A, Krishnan K, Maurya A, Sarkar N. In silico screening of drugs to find potential gamma-secretase inhibitors using pharmacophore modeling, QSAR and molecular docking studies. Comb Chem High T Scr. 2014;17(9):770-780
Chávez-Gutiérrez L, Tolia A, Maes E, Li T, Wong PC, de Strooper B. Glu332 in the Nicastrin ectodomain is essential for γ-secretase complex maturation but not for its activity. J Biol Chem. 2008;283(29):20096-20105. DOI: https://doi.org/10.1074/jbc.M803040200
Crump C. Target identification and mechanism of gamma-secretase modulators and inhibitors as Alzheimer's disease therapeutics [dissertation]. CORNELL UNIVERSITY; 2013. DOI: http://search.proquest.com/docview/1444628197?accountid=49118
Puentes NC, Orozco DP, Díaz FC. Curcumin analogues as promissory compounds for inhibition of β-secretase, γ-secretase and GSK-3β implicated in Alzheimer’s disease: In silico study. Biomed Pharmacol J. 2022;15(1).
Shelton CC, Zhu L, Chau D, Yang L, Wang R, Djaballah H, et al.Modulation of γ-secretase specificity using small molecule allosteric inhibitors. Proc Natl Acad Sci U S A. 2009;106(48):20228-20233. DOI: https://doi.org/10.1073/pnas.091075710
Ghosh AK, Brindisi M, Tang J. Developing β-secretase inhibitors for treatment of Alzheimer’s disease. J Neurochem. 2012;120:71-83. DOI: https://doi.org/10.1111/j.1471-4159.2011.07476.x
Yi Mok N, Chadwick J, Kellett KAB, Hooper NM, Johnson AP, Fishwick CWG. Discovery of novel non-peptide inhibitors of BACE-1 using virtual high-throughput screening. Bioorg Med Chem Lett. 2009;19(23):6770-6774. DOI: https://doi.org/10.1016/j.bmcl.2009.09.103
Choi RJ, Roy A, Jung HJ, Ali MY, Min B-S, Park CH, et al.BACE1 molecular docking and anti-Alzheimer's disease activities of ginsenosides. J Ethnopharmacol. 2016;190:219-230. DOI: https://doi.org/10.1016/j.jep.2016.06.013
Bhakta HK, Park CH, Yokozawa T, Min B-S, Jung HA, Choi JS. Kinetics and molecular docking studies of loganin, morroniside and 7-O-galloyl-d-sedoheptulose derived from Corni fructus as cholinesterase and β-secretase 1 inhibitors. Arch Pharm Res. 2016;39(6):794-805. DOI: https://doi.org/10.1007/s12272-016-0745-5
Rueeger H, Lueoend R, Rogel O, Rondeau J-M, Möbitz H, Machauer R, et al.Discovery of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: Structure-based design and in vivo reduction of amyloid β-peptides. J Med Chem. 2012;55(7):3364-3386. DOI: https://doi.org/10.1021/jm300069y
Ahn JS, Radhakrishnan ML, Mapelli M, Choi S, Tidor B, Cuny GD, et al.Defining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation. Chem Biol. 2005;12(7):811-823. DOI: https://doi.org/10.1016/j.chembiol.2005.05.011
Tsai L-H, Lee M-S, Cruz J. Cdk5, a therapeutic target for Alzheimer’s disease? Biochim Biophys Acta. 2004;1697(1–2):137-142. DOI: https://doi.org/10.1016/j.bbapap.2003.11.019
Lau L-F, Seymour PA, Sanner MA, Schachter JB. Cdk5 as a drug target for the treatment of Alzheimer’s disease. J Mol Neurosci. 2002;19(3):267-273. DOI: https://doi.org/10.1385/jmn:19:3:267
Helal CJ, Sanner MA, Cooper CB, Gant T, Adam M, Lucas JC, et al.Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer’s disease. Bioorg Med Chem Lett. 2004;14(22):5521-5525. DOI: https://doi.org/10.1016/j.bmcl.2004.09.006
Bajda M, Guzior N, Ignasik M, Malawska B. Multi-target-directed ligands in Alzheimer's disease treatment. Curr Med Chem. 2011;18(32):4949-4975. DOI: https://doi.org/10.2174/092986711797535245
Khan H, Ullah H, Aschner M, Cheang WS, Akkol EK. Neuroprotective effects of quercetin in Alzheimer's disease. Biomolecules. 2019;10(1):59. DOI: https://doi.org/10.3390/biom10010059
Zhang ZQ, Hölscher C. GIP has neuroprotective effects in Alzheimer and Parkinson's disease models. Peptides. 2020 Mar;125:170184. DOI: https://doi.org/10.1016/j.peptides.2019.170184
Moon J-Y, Kim E-S, Choi S-J, Kim J-I, Choi N-S, Lee K, et al.Protective effect of the ethyl acetate-fraction of methanol extract of Ophiophogon japonicus on amyloid beta peptide-induced cytotoxicity in PC12 cells. J Life Sci. 2019;29(2):173-180. DOI: https://doi.org/10.5352/JLS.2019.29.2.173
Shin M, Liu QF, Choi B, Shin C, Lee B, Yuan C, et al.Neuroprotective effects of limonene (+) against Aβ42-induced neurotoxicity in a Drosophila model of Alzheimer's disease. Biol Pharm Bull. 2020 Mar 1;43(3):409-417. DOI: https://doi.org/10.1248/bpb.b19-00495
Chen XY, Du YF, Chen L. Neuropeptides exert neuroprotective effects in Alzheimer's disease models. Neurochem Int. 2020 Jun;138:104771. DOI: https://doi.org/10.3389/fnmol.2018.00493
Yi S, Chen S, Xiang J, Tan J, Huang K, Zhang H, et al.Genistein exerts a cell-protective effect via Nrf2/HO-1/PI3K signaling in Ab25-35-induced Alzheimer's disease models in vitro. Folia Histochem Cytobiol. 2021;59(1):49-56. DOI: https://doi.org/10.5603/FHC.a2021.0006. PMID: 33605427.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Nerlis Pajaro-Castro, Elkin Torres-Sierra, , Edwar Cortes-Gonzalez, Margaret Paternina , Erwin Camacho , Pedro Blanco
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright Notice and Open Access Statement
The Journal Vitae works under the Open Access license, and the published manuscripts remain available for the public, both on the Journal's website and in databases, under the Creative Commons license, "Noncommercial Attribution" and "Share alike" systems, adopted in Colombia. Hence, when the authors agree to publish in the Journal Vitae, they will not have the right to economic retributions on publications and reproductions through different diffusion media. The documents are freely available to the internet public, permitting users to read, download, copy, distribute, print, search, or link to the full texts and pass them as data to software. The only constraint on reproduction and distribution, should be to give authors control over the integrity of their work and the right to be appropriately acknowledged and cited.
Authors declare that:
-
They are the intellectual property owners and are responsible for all the information stated in the article.
-
This manuscript has not been submitted or published in other printed or digital media. They accept the responsibility for the judgments, opinions, and points of view expressed in the published article and, therefore, they exonerate Universidad de Antioquia and Journal Vitae from any process.
-
They exempt Universidad de Antioquia and Journal Vitae from settling conflicts or disputes related to the authorship of the referred article.
-
They accept the revision of the original manuscript by suitable personnel, and they bind themselves to perform the corrections appointed or suggested by the assessors.
-
Therefore, they know the editorial process and will not bind the Editorial Board of the Journal to assume any obligations regarding the volume and issue in which the article is published.
-
They transfer the rights of publication, reprinting, and distribution of the article from the moment of its approval, in print and digital format, without the right to economic rewards, and under the licensing conditions considered relevant by Journal Vitae.
-
They fully authorize Universidad de Antioquia and Journal Vitae to submit the published material to the diverse databases and indexing systems where the Journal can be found to comply with the requirements of the regulatory authorities to maintain the national classification of journals.
-
They will assume the article publication costs established for the current issue, and they will make the payment as soon as they are informed about the volume and the issue in which the final version of the article is published.
-
After the article is published, you can share digital or printed copies in a noncommercial manner. You will be able to use the paper in your institution or company for educational or research purposes, including the use in course programs.
Conflict of interest: Authors are responsible for recognizing and disclosing any financial or other benefits that could be perceived to bias their work, acknowledging all financial support and any personal connections with potential sponsors. Examples of such conflicts include receiving research funds or honoraria, serving on advisory boards, stock ownership, or employment and consulting arrangements. Authors without such connections should clearly state that they have no financial support or personal relationships that could be perceived to bias their work. All conflicts of interest should be disclosed on the author's identification page of the manuscript.
